Fiche publication
Date publication
août 2005
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc
Tous les auteurs :
Acres B, Limacher JM
Lien Pubmed
Résumé
The cancer-associated antigen MUC1 is overexpressed and modified by tumor cells in over half of all cancer cases. Despite various complexities associated with this antigen, it is well worth pursuing as a vaccine for the immunotherapy of cancer. In this review, the authors describe the discovery of MUC1 and its association with cancer, recent observations showing that the immunology of MUC1 is complicated, animal data showing that it can be a target for immune-mediated tumor rejection, and finally, preliminary clinical results to show that vaccine-based immunotherapy with MUC1 does have an impact on the therapy of cancer.
Référence
Expert Rev Vaccines. 2005 Aug;4(4):493-502.
